利用金属螯合物对单克隆抗体进行放射性标记的新方法。
Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
作者信息
Gansow O A
机构信息
Chemistry Section, Radiation Oncology Branch, National Institutes of Health, Bethesda, MD 20892.
出版信息
Int J Rad Appl Instrum B. 1991;18(4):369-81. doi: 10.1016/0883-2897(91)90063-q.
Monoclonal antibodies (mAbs) radiolabeled by use of metal chelators are being investigated in the laboratory for use in clinical trials. 111In is presently employed for diagnostic scintigraphy, but its applications are limited by substantive and persistant uptake of radiometal in the liver. Much current research is focused on performing cancer therapy with 90Y and 212Bi chelate-linked mAbs. This report chronicles the development and evaluation of chelating agents for 111In-radioimmunoimaging and 90Y- and 212Bi-radioimmunotherapy.
利用金属螯合剂进行放射性标记的单克隆抗体（mAb）正在实验室中接受研究，以用于临床试验。目前，铟-111（¹¹¹In）被用于诊断性闪烁显像，但由于肝脏对放射性金属的大量持续摄取，其应用受到限制。当前许多研究都集中在使用钇-90（⁹⁰Y）和铋-212（²¹²Bi）螯合物连接的单克隆抗体进行癌症治疗。本报告记录了用于¹¹¹In放射免疫显像以及⁹⁰Y和²¹²Bi放射免疫治疗的螯合剂的开发与评估。
Zotero 插件